pcdna3.1_man

pcDNA3.1(-)

Catalog nos. V790-20 and V795-20, respectively

Version I

081401

28-0104

www.invitrogen.com

tech_service@invitrogen.com

ii

Table of Contents

Table of Contents (iii)

Important Information (v)

Purchaser Notification (vi)

Methods (1)

Overview (1)

Cloning into pcDNA3.1 (2)

Transfection (6)

Creation of Stable Cell Lines (7)

Appendix (10)

pcDNA3.1 Vectors (10)

pcDNA3.1/CAT (12)

Technical Service (13)

References (15)

iii

iv

Important Information

Contents pcDNA3.1 is supplied as follows:

Catalog no.Contents

V790-2020 µg pcDNA3.1(+), lyophilized in TE, pH 8.0

20 µg pcDNA3.1/CAT, lyophilized in TE, pH 8.0

V795-2020 µg pcDNA3.1(-), lyophilized in TE, pH 8.0

20 µg pcDNA3.1/CAT, lyophilized in TE, pH 8.0 Shipping/Storage Lyophilized plasmids are shipped at room temperature and should be stored at -20°C.

Product Qualification Each of the pcDNA3.1 vectors is qualified by restriction enzyme digestion with specific restriction enzymes as listed below. Restriction digests must demonstrate the correct banding pattern when electrophoresed on an agarose gel. The table below lists the restriction enzymes and the expected fragments.

vPurchaser Notification

Introduction Use of pcDNA3.1 is covered under a number of different licenses as described below.

CMV Promoter Use of the CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839

owned and licensed by the University of Iowa Research Foundation and may be used for

research purposes only. Commercial users must obtain a license to these patents directly

from the University of Iowa Research Foundation. Inquiries for commercial use should be

directed to:

Brenda Akins

University of Iowa Research Foundation (UIRF)

214 Technology Innovation Center

Iowa City, IA 52242

Phone:319-335-4549

BGH Polyadenylation Signal The bovine growth hormone (BGH) polyadenylation sequence is licensed under U.S. Patent No. 5,122,458 for research purposes only. “Research purposes” means uses directed to the identification of useful recombinant proteins and the investigation of the recombinant expression of proteins, which uses shall in no event include any of the following:

a.any use in humans of a CLAIMED DNA or CLAIMED CELL;

b.any use in human of protein or other substance expressed or made at any stage of its

production with the use of a CLAIMED DNA or a CLAIMED CELL;

c.any use in which a CLAIMED DNA or CLAIMED CELL would be sold or

transferred to another party other than Invitrogen, its AFFILIATE, or its

SUBLICENSEE;

d.any use in connection with the expression or production of a product intended for

sale or commercial use; or

e.any use for drug screening or drug development.

Inquiries for commercial use should be directed to:

Bennett Cohen, Ph.D.

Research Corporation Technologies

101 North Wilmot Road, Suite 600

Tucson, AZ 85711-3335

Tel: 1-520-748-4400

Fax: 1-520-748-0025

vi

Methods

Overview

Introduction pcDNA3.1(+) and pcDNA3.1(-) are 5.4 kb vectors derived from pcDNA3 and designed for high-level stable and transient expression in mammalian hosts. High-level stable and

non-replicative transient expression can be carried out in most mammalian cells. The

vectors contain the following elements:

•Human cytomegalovirus immediate-early (CMV) promoter for high-level expression

in a wide range of mammalian cells

•Multiple cloning sites in the forward (+) and reverse (-) orientations to facilitate

cloning

•

•Episomal replication in cells lines that are latently infected with SV40 or that express

the SV40 large T antigen (e.g. COS-1, COS-7)

The control plasmid, pcDNA3.1/CAT, is included for use as a positive control for

transfection and expression in the cell line of choice.

Experimental Outline Use the following outline to clone and express your gene of interest in pcDNA3.1.

1.Consult the multiple cloning sites described on pages 3-4 to design a strategy to clone

your gene into pcDNA3.1.

2.Ligate your insert into the appropriate vector and transform into E. coli. Select

transformants on LB plates containing 50 to 100 µg/ml ampicillin.

3.Analyze your transformants for the presence of insert by restriction digestion.

4.Select a transformant with the correct restriction pattern and use sequencing to

confirm that your gene is cloned in the proper orientation.

5.Transfect your construct into the mammalian cell line of interest using your own

method of choice. Generate a stable cell line, if desired.

6.Test for expression of your recombinant gene by western blot analysis or functional

assay.Cloning into pcDNA3.1

Introduction Diagrams are provided on pages 3-4 to help you design a cloning strategy for ligating your gene of interest into pcDNA3.1. General considerations for cloning and transformation are

listed below.

General Molecular Biology Techniques For help with DNA ligations, E. coli transformations, restriction enzyme analysis, purification of single-stranded DNA, DNA sequencing, and DNA biochemistry, please refer to Molecular Cloning: A Laboratory Manual (Sambrook et al., 19) or Current Protocols in Molecular Biology (Ausubel et al., 1994).

E. coli Strain Many E. coli strains are suitable for the propagation of this vector including TOP10F´,

DH5α™-T1R, and TOP10. We recommend that you propagate vectors containing inserts in

E. coli strains that are recombination deficient (rec A) and endonuclease A-deficient

(end A).

For your convenience, TOP10F´ is available as chemically competent or electrocompetent

cells from Invitrogen.

Item Quantity Catalog no.

One Shot® TOP10F´ (chemically competent cells)21 x 50 µl C3030-03

Electrocomp™ TOP10F´ 5 x 80 µl C665-55

Ultracomp™ TOP10F´ (chemically competent cells) 5 x 300 µl C665-03

Transformation Method You may use any method of your choice for transformation. Chemical transformation is the most convenient for most researchers. Electroporation is the most efficient and the method of choice for large plasmids.

Maintenance of pcDNA3.1To propagate and maintain pcDNA3.1, we recommend resuspending the vector in 20 µl sterile water to make a 1 µg/µl stock solution. Store the stock solution at -20°C.

Use this stock solution to transform a rec A,

end A E. coli strain like TOP10F´, DH5α™-T1R, TOP10, or equivalent. Select transformants on LB plates containing 50 to

100 µg/ml ampicillin. Be sure to prepare a glycerol stock of your plasmid-containing E. coli strain for long-term storage (see page 5).

Cloning Considerations pcDNA3.1(+) and pcDNA3.1(-) are nonfusion vectors. Your insert must contain a Kozak translation initiation sequence and an ATG start codon for proper initiation of translation (Kozak, 1987; Kozak, 1991; Kozak, 1990). An example of a Kozak consensus sequence is provided below. Please note that other sequences are possible (see references above), but the G or A at position -3 and the G at position +4 are the most critical for function note that the Xba I site contains an internal stop codon (TCTAGA).

continued on next page

Multiple Cloning

Site of

pcDNA3.1(+)Below is the multiple cloning site for pcDNA3.1(+). Restriction sites are labeled to indicate the cleavage site. The Xba I site contains an internal stop codon (TCTAGA). The multiple cloning site has been confirmed by sequencing and functional testing. The

complete sequence of pcDNA3.1(+) is available for downloading from our web site (www.invitrogen.com ) or from Technical Service (see page 13). For a map and a description of the features of pcDNA3.1(+), please refer to the Appendix , pages 10-11.

1109TCCTTTCCTA ATAAAATGAG GAAATTGCAT CAAT TA TA BGH poly (A) site CATTGACGTC AATGGGAGTT TGTTTTGGCA CCAAAATCAA CGGGACTTTC CAAAATGTCG TAACAACTCC GCCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT AGTCTAGAGG GCCCGTTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC CATCTGTTGT TTGCCCCTCC CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCACTG 6

749

809

869

929

9

1049

enhancer region (3´ end)

*Please note that there are two Bst X I sites in the polylinker.

continued on next page

Multiple Cloning

Site of

pcDNA3.1(-)Below is the multiple cloning site for pcDNA3.1(-). Restriction sites are labeled to indicate the cleavage site. The Xba I site contains an internal stop codon (TCTAGA). The multiple cloning site has been confirmed by sequencing and functional testing. The

complete sequence of pcDNA3.1(-) is available for downloading from our web site (www.invitrogen.com ) or from Technical Service (see page 13). For a map and a description of the features of pcDNA3.1(-), please see the Appendix , pages 10-11.

Hin d III CAAT TA TA Bam H I Bst X I*Eco R I Eco R V Bst X I*BGH poly (A) site Kpn I Afl II Pme I Asp 718 I pcDNA3.1/BGH reverse priming site CCTTTCCTAA TAAAATGAGG AAATTGCATC ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT GGTACCAAGC TTAAGTTTAA ACCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC GCCGCCACTG TGCTGGATAT CTGCAGAATT CCACCACACT GGACTAGTGG ATCCGAGCTC TAACAACTCC GCCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT CATTGACGTC AATGGGAGTT TGTTTTGGCA CCAAAATCAA CGGGACTTTC CAAAATGTCG 1109

1049

9

929

869

809

749

6

enhancer region (3´ end)

*Please note that there are two Bst X I sites in the polylinker.

continued on next page

We recommend that you sequence your construct with the T7 Promoter and BGH Reverse

primers (Catalog nos. N560-02 and N575-02, respectively) to confirm that your gene is in the

correct orientation for expression and contains an ATG and a stop codon. Please refer to the

diagrams on pages 3-4 for the sequences and location of the priming sites. The primers are

available separately from Invitrogen in 2 µg aliquots.

Preparing a

Glycerol Stock

Once you have identified the correct clone, purify the colony and make a glycerol stock for

long-term storage. You should keep a DNA stock of your plasmid at -20°C.

•Streak the original colony out on an LB plate containing 50 µg/ml ampicillin. Incubate

the plate at 37°C overnight.

•Isolate a single colony and inoculate into 1-2 ml of LB containing 50 µg/ml ampicillin.

•Grow the culture to mid-log phase (OD600 = 0.5-0.7).

•Mix 0.85 ml of culture with 0.15 ml of sterile glycerol and transfer to a cryovial.

•Store at -80°C.Transfection

Introduction Once you have verified that your gene is cloned in the correct orientation and contains an initiation ATG and a stop codon, you are ready to transfect your cell line of choice. We

recommend that you include the positive control vector and a mock transfection (negative

control) to evaluate your results.

Plasmid Preparation Plasmid DNA for transfection into eukaryotic cells must be clean and free from phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipids decreasing transfection efficiency. We recommend isolating plasmid DNA using the S.N.A.P.™ MiniPrep Kit (10-15 µg DNA, Catalog no. K1900-01), the S.N.A.P. ™MidiPrep Kit (10-200 µg DNA, Catalog no. K1910-01), or CsCl gradient centrifugation.

Methods of Transfection For established cell lines (e.g. HeLa), please consult original references or the supplier of your cell line for the optimal method of transfection. We recommend that you follow exactly the protocol for your cell line. Pay particular attention to medium requirements, when to pass the cells, and at what dilution to split the cells. Further information is provided in Current Protocols in Molecular Biology (Ausubel et al., 1994).

Methods for transfection include calcium phosphate (Chen and Okayama, 1987; Wigler et al., 1977), lipid-mediated (Felgner et al., 19; Felgner and Ringold, 19) and electroporation (Chu et al., 1987; Shigekawa and Dower, 1988). Invitrogen offers the Calcium Phosphate Transfection Kit (Catalog no. K2780-01) and a large selection of reagents for transfection. For more information, please refer to our World Wide Web site (www.invitrogen.com) or call Technical Service (see page 13).

Positive Control pcDNA3.1/CAT is provided as a positive control vector for mammalian transfection and expression (see page 12) and may be used to optimize transfection conditions for your

cell line. The gene encoding chloramphenicol acetyl transferase (CAT) is expressed in

mammalian cells under the control of the CMV promoter. A successful transfection will

result in CAT expression that can be easily assayed (see below).

Assay for CAT Protein You may assay for CAT expression by ELISA assay, western blot analysis, fluorometric assay, or radioactive assay (Ausubel et al., 1994; Neumann et al., 1987). If you wish to detect CAT protein using western blot analysis, you may use the Anti-CAT Antiserum (Catalog no. R902-25) available from Invitrogen. Other kits to assay for CAT protein using ELISA assay are available from Roche Molecular Biochemicals (Catalog no. 1 363 727) and Molecular Probes (Catalog no. F-2900).

Creation of Stable Cell Lines

Introduction The pcDNA3.1(+) and pcDNA3.1(-) vectors contain the neomycin resistance gene for

selection of stable cell lines using neomycin (Geneticin®). We recommend that you test

the sensitivity of your mammalian host cell to Geneticin® as natural resistance varies

among cell lines. General information and guidelines are provided in this section for your

convenience.

Geneticin®Selective Antibiotic Geneticin® Selective Antibiotic blocks protein synthesis in mammalian cells by interfering with ribosomal function. It is an aminoglycoside, similar in structure to neomycin, gentamycin, and kanamycin. Expression of the bacterial aminoglycoside phosphotransferase gene (APH), derived from Tn5, in mammalian cells results in detoxification of Geneticin®(Southern and Berg, 1982).

Geneticin®Selection Guidelines Geneticin® Selective Antibiotic is available from Invitrogen (Catalog no. 10486-025). Use as follows:

•Prepare Geneticin® in a buffered solution (e.g. 100 mM HEPES, pH 7.3).

•Use 100 to 800 µg/ml of Geneticin® in complete medium.

•Calculate concentration based on the amount of active drug (check the lot label).•Test varying concentrations of Geneticin® on your cell line to determine the

concentration that kills your cells (see below). Cells differ in their susceptibility to Geneticin®.

Cells will divide once or twice in the presence of lethal doses of Geneticin®, so the effects of the drug take several days to become apparent. Complete selection can take up to 3 weeks of growth in selective media.

Determination of Antibiotic Sensitivity To successfully generate a stable cell line expressing your gene of interest from

pcDNA3.1, you need to determine the minimum concentration of Geneticin® required to kill your untransfected host cell line. We recommend that you test a range of concentrations to ensure that you determine the minimum concentration necessary for your host cell line.

1.Plate or split a confluent plate so the cells will be approximately 25% confluent.

Prepare a set of 7 plates. Allow cells to adhere overnight.

2.The next day, substitute culture medium with medium containing varying

concentrations of Geneticin® (0, 50, 100, 200, 400, 600, 800 µg/ml Geneticin®).

3.Replenish the selective media every 3-4 days, and observe the percentage of surviving

cells.

4.Count the number of viable cells at regular intervals to determine the appropriate

concentration of Geneticin® that prevents growth within 2-3 weeks after addition of Geneticin®.

continued on next pagePossible Sites for Linearization of pcDNA3.1(+)Prior to transfection, we recommend that you linearize the pcDNA3.1(+) vector. Linearizing pcDNA3.1(+) will decrease the likelihood of the vector integrating into the genome in a way that disrupts the gene of interest or other elements required for expression in mammalian cells. The table below lists unique restriction sites that may be used to linearize your construct prior to transfection. Other unique restriction sites are possible. Be sure that your insert does not contain the restriction enzyme site you wish to use to linearize your vector.

Enzyme Restriction Site (bp)Location Supplier

Bgl II12Upstream of CMV promoter Invitrogen, Catalog no. 15213-028 Mfe I161Upstream of CMV promoter New England Biolabs

Bst1107 I3236End of SV40 polyA AGS*, Fermentas, Takara, Roche

Mol. Biochemicals

Eam1105 I4505Ampicillin gene AGS*, Fermentas, Takara

Pvu I4875Ampicillin gene Invitrogen, Catalog no. 25420-019 Sca I4985Ampicillin gene Invitrogen, Catalog no. 15436-017 Ssp I5309bla promoter Invitrogen, Catalog no. 15458-011 *Angewandte Gentechnologie Systeme

Possible Sites for Linearization of pcDNA3.1(-)The table below lists unique restriction sites that may be used to linearize your

pcDNA3.1(-) construct prior to transfection. Other unique restriction sites are possible. Be sure that your insert does not contain the restriction enzyme site you wish to use to linearize your vector.

Enzyme Restriction Site (bp)Location Supplier

Bgl II12Upstream of CMV promoter Invitrogen, Catalog no. 15213-028 Mfe I161Upstream of CMV promoter New England Biolabs

Bst1107 I3235End of SV40 polyA AGS*, Fermentas, Takara, Roche

Mol. Biochemicals

Eam1105 I4504Ampicillin gene AGS*, Fermentas, Takara

Pvu I4874Ampicillin gene Invitrogen, Catalog no. 25420-019 Sca I4984Ampicillin gene Invitrogen, Catalog no. 15436-017 Ssp I5308bla promoter Invitrogen, Catalog no. 15458-011 *Angewandte Gentechnologie Systeme

continued on next pageSelection of Stable Integrants Once you have determined the appropriate Geneticin® concentration to use for selection in your host cell line, you can generate a stable cell line expressing your gene of interest.

1.Transfect your mammalian host cell line with your pcDNA3.1 construct using the

desired protocol. Remember to include a plate of untransfected cells as a negative

control and the pcDNA3.1/CAT plasmid as a positive control.

2.24 hours after transfection, wash the cells and add fresh medium to the cells.

3.48 hours after transfection, split the cells into fresh medium containing Geneticin® at

the pre-determined concentration required for your cell line. Split the cells such that they are no more than 25% confluent.

4.Feed the cells with selective medium every 3-4 days until Geneticin®-resistant foci can

be identified.

5.Pick and expand colonies in 96- or 48-well plates.

Appendix

pcDNA3.1 Vectors

Map of

pcDNA3.1(+) and pcDNA3.1(-)

The figure below summarizes the features of the pcDNA3.1(+) and pcDNA3.1(-) vectors.The complete sequences for pcDNA3.1(+) and pcDNA3.1(-) are available for down-loading from our World Wide Web site (www.invitrogen.com ) or from Technical Service (see page 13). Details of the multiple cloning sites are shown on page 3 for pcDNA3.1(+) and page 4 for pcDNA3.1(-).

Comments for pcDNA3.1 (+) 5428 nucleotides

CMV promoter: bases 232-819

T7 promoter/priming site: bases 863-882Multiple cloning site: bases 5-1010

BGH polyadenylation sequence: bases 1028-1252f1 origin: bases 1298-1726

SV40 early promoter and origin: bases 1731-2074Neomycin resistance gene (ORF): bases 2136-2930SV40 early polyadenylation signal: bases 3104-3234pUC origin: bases 3617-4287 (complementary strand)

Ampicillin resistance gene (bla ): bases 4432-5428 (complementary strand) ORF: bases 4432-5292 (complementary strand)

Ribosome binding site: bases 5300-5304 (complementary strand) bla promoter (P3): bases 5327-5333 (complementary strand)

I I (+)( )

continued on next page

Features of pcDNA3.1(+) and pcDNA3.1(-)pcDNA3.1(+) (5428 bp) and pcDNA3.1(-) (5427 bp) contain the following elements. All features have been functionally tested.

Feature Benefit

Human cytomegalovirus (CMV)

immediate-early promoter/enhancer

Permits efficient, high-level expression of

your recombinant protein (Andersson et al.,

19; Boshart et al., 1985; Nelson et al.,

1987)

T7 promoter/priming site Allows for in vitro transcription in the sense

orientation and sequencing through the

insert

Multiple cloning site in forward or

reverse orientation

Allows insertion of your gene and

facilitates cloning

Bovine growth hormone (BGH)

polyadenylation signal

Efficient transcription termination and

polyadenylation of mRNA (Goodwin and

Rottman, 1992)

f1 origin Allows rescue of single-stranded DNA

SV40 early promoter and origin Allows efficient, high-level expression of

the neomycin resistance gene and episomal

replication in cells expressing SV40 large T

antigen

Neomycin resistance gene Selection of stable transfectants in

mammalian cells (Southern and Berg,

1982)

SV40 early polyadenylation signal Efficient transcription termination and

polyadenylation of mRNA

pUC origin High-copy number replication and growth

in E. coli

Ampicillin resistance gene (β-lactamase)Selection of vector in E. colipcDNA3.1/CAT

Description pcDNA3.1/CAT is a 6217 bp control vector containing the gene for CAT. It was

constructed by digesting pcDNA3.1(+) with Xho I and Xba I and treating with Klenow.

An 800 bp Hin d III fragment containing the CAT gene was treated with Klenow and then

ligated into pcDNA3.1(+).

Map of Control Vector The figure below summarizes the features of the pcDNA3.1/CAT vector. The complete nucleotide sequence for pcDNA3.1/CAT is available for downloading from our World Wide Web site (www.invitrogen.com) or by contacting Technical Service (see page 13).

Comments for pcDNA3.1(+)/CAT

6217 nucleotides

CMV promoter: bases 232-819

CAT ORF: bases 1027-1686

pcDNA3.1/BGH reverse priming site: bases 1811-1828

BGH polyadenylation sequence: bases 1817-2041

f1 origin: bases 2087-2515

SV40 early promoter and origin: bases 2520-2863

Neomycin resistance gene (ORF): bases 2925-3719

SV40 early polyadenylation sequence: bases 33-4023

pUC origin: bases 4406-5076 (complementary strand)

Ampicillin resistance gene (ORF): bases 5221-6081 (complementary strand)

Technical Service

Visit the Invitrogen Web Resource using your World Wide Web browser. At the site, you

can:

•Get the scoop on our hot new products and special product offers

•View and download vector maps and sequences

•Download manuals in Adobe® Acrobat® (PDF) format

•Explore our catalog with full color graphics

•Obtain citations for Invitrogen products

•Request catalog and product literature

Once connected to the Internet, launch your web browser (Internet Explorer 5.0 or newer

or Netscape 4.0 or newer), then enter the following location (or URL):

http://www.invitrogen.com

...and the program will connect directly. Click on underlined text or outlined graphics to

explore. Don't forget to put a bookmark at our site for easy reference!

Contact us For more information or technical assistance, please call, write, fax, or email. Additional

international offices are listed on our web page (www.invitrogen.com).

United States Headquarters:Japanese Headquarters European Headquarters:

Invitrogen Corporation Invitrogen Japan K.K.Invitrogen Ltd

1600 Faraday Avenue Nihonbashi Hama-Cho Park Bldg. 4F 3 Fountain Drive

Carlsbad, CA 92008 USA2-35-4, Hama-Cho, Nihonbashi Inchinnan Business Park

Tel: 1 760 603 7200Tel: 81 3 3663 7972Paisley PA4 9RF, UK

Tel (Toll Free): 1 800 955 6288Fax: 81 3 3663 8242Tel (Free Phone Orders): 0800 269 210 Fax: 1 760 602 6500E-mail: jpinfo@invitrogen.com Tel (General Enquiries): 0800 5345 5345

Fax: +44 (0) 141 814 6287

E-mail:

tech_service@invitrogen.com E-mail: eurotech@invitrogen.com

MSDS Requests To request an MSDS, please visit our web site (www.invitrogen.com) and follow the

instructions below.

1.On the home page, go to the left-hand column under ‘Technical Resources’ and

select ‘MSDS Requests’.

2.Follow instructions on the page and fill out all the required fields.

3.To request additional MSDSs, click the ‘Add Another’ button.

4.All requests will be faxed unless another method is selected.

5.When you are finished entering information, click the ‘Submit’ button. Your MSDS

will be sent within 24 hours.

continued on next page

13Technical Service, continued

Emergency Information In the event of an emergency, customers of Invitrogen can call the 3E Company, 24 hours a day, 7 days a week for disposal or spill information. The 3E Company can also connect the customer with poison control or with the University of California at San Diego Medical Center doctors.

3E Company

Voice: 1-760-602-8700

Limited Warranty Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should

have any questions or concerns about an Invitrogen product or service, please contact our

Technical Service Representatives.

Invitrogen warrants that all of its products will perform according to the specifications stated on the

certificate of analysis. The company will replace, free of charge, any product that does not meet

those specifications. This warranty limits Invitrogen Corporation’s liability only to the cost of the

product. No warranty is granted for products beyond their listed expiration date. No warranty is

applicable unless all product components are stored in accordance with instructions. Invitrogen

reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a

specified method in writing prior to acceptance of the order.

Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the

occasional typographical or other error is inevitable. Therefore Invitrogen makes no warranty of

any kind regarding the contents of any publications or documentation. If you discover an error in

any of our publications, please report it to our Technical Service Representatives.

Invitrogen assumes no responsibility or liability for any special, incidental, indirect or

consequential loss or damage whatsoever. The above limited warranty is sole and exclusive.

No other warranty is made, whether expressed or implied, including any warranty of

merchantability or fitness for a particular purpose.

14References

Andersson, S., Davis, D. L., Dahlbäck, H., Jörnvall, H., and Russell, D. W. (19). Cloning, Structure, and

Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. J.

Biol. Chem. 2, 8222-8229.

Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994).

Current Protocols in Molecular Biology (New York: Greene Publishing Associates and Wiley-Interscience).

Boshart, M., Weber, F., Jahn, G., Dorsch-Häsler, K., Fleckenstein, B., and Schaffner, W. (1985). A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus. Cell 41, 521-530.

Chen, C., and Okayama, H. (1987). High-Efficiency Transformation of Mammalian Cells by Plasmid DNA. Mol.

Cell. Biol. 7, 2745-2752.

Chu, G., Hayakawa, H., and Berg, P. (1987). Electroporation for the Efficient Transfection of Mammalian Cells with DNA. Nuc. Acids Res. 15, 1311-1326.

Felgner, P. L., Holm, M., and Chan, H. (19). Cationic Liposome Mediated Transfection. Proc. West. Pharmacol.

Soc. 32, 115-121.

Felgner, P. L., and Ringold, G. M. (19). Cationic Liposome-Mediated Transfection. Nature 337, 387-388.

Goodwin, E. C., and Rottman, F. M. (1992). The 3´-Flanking Sequence of the Bovine Growth Hormone Gene

Contains Novel Elements Required for Efficient and Accurate Polyadenylation. J. Biol. Chem. 267, 16330-16334. Kozak, M. (1987). An Analysis of 5´-Noncoding Sequences from 699 Vertebrate Messenger RNAs. Nuc. Acids Res.

15, 8125-8148.

Kozak, M. (1991). An Analysis of Vertebrate mRNA Sequences: Intimations of Translational Control. J. Cell Biol.

115, 887-903.

Kozak, M. (1990). Downstream Secondary Structure Facilitates Recognition of Initiator Codons by Eukaryotic Ribosomes. Proc. Natl. Acad. Sci. USA 87, 8301-8305.

Nelson, J. A., Reynolds-Kohler, C., and Smith, B. A. (1987). Negative and Positive Regulation by a Short Segment

in the 5´-Flanking Region of the Human Cytomegalovirus Major Immediate-Early Gene. Mol. Cell. Biol. 7, 4125-

4129.

Neumann, J. R., Morency, C. A., and Russian, K. O. (1987). A Novel Rapid Assay for Chloramphenicol Acetyltransferase Gene Expression. BioTechniques 5, 444-447.

Sambrook, J., Fritsch, E. F., and Maniatis, T. (19). Molecular Cloning: A Laboratory Manual, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press).

Shigekawa, K., and Dower, W. J. (1988). Electroporation of Eukaryotes and Prokaryotes: A General Approach to

the Introduction of Macromolecules into Cells. BioTechniques 6, 742-751.

Southern, P. J., and Berg, P. (1982). Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial

Gene Under Control of the SV40 Early Region Promoter. J. Molec. Appl. Gen. 1, 327-339.

Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., and Axel, R. (1977). Transfer of Purified Herpes

Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell 11, 223-232.

©1997-2001 Invitrogen Corporation. All rights reserved.

15